原发性脑肿瘤患者抑郁症的药物治疗
Pharmacological treatment of depression in people with a primary brain tumour.
作者信息
Beevers Zachary, Hussain Sana, Boele Florien W, Rooney Alasdair G
机构信息
School of Medicine, University of Leeds, Leeds, UK.
Leeds Institute of Health Sciences and Leeds Institute of Cancer and Pathology, University of Leeds and Leeds Cancer Centre, Leeds, UK.
出版信息
Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD006932. doi: 10.1002/14651858.CD006932.pub4.
BACKGROUND
This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013. People with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, they are also at high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear.
OBJECTIVES
To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour.
SEARCH METHODS
We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019).
SELECTION CRITERIA
We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour.
DATA COLLECTION AND ANALYSIS
No studies met the inclusion criteria.
MAIN RESULTS
We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour.
AUTHORS' CONCLUSIONS: We identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional information to change these conclusions.
背景
这是发表于2010年第3期的Cochrane系统评价的第二次更新版本，首次更新于2013年第5期。原发性脑肿瘤患者常出现抑郁症，可能会接受药物治疗。然而，他们也有癫痫发作、认知障碍和疲劳的高风险，所有这些都是抗抑郁药潜在的不良副作用。原发性脑肿瘤患者药物治疗抑郁症的益处或危害尚不清楚。
目的
评估原发性脑肿瘤患者药物治疗抑郁症的益处和危害。
检索方法
我们更新了检索，纳入截至2019年9月的Cochrane系统评价数据库、医学期刊数据库、荷兰医学文摘数据库和心理学文摘数据库。与原始系统评价一样，我们还手工检索了《神经肿瘤学》《神经肿瘤学杂志》《神经病学、神经外科学与精神病学杂志》以及《临床肿瘤学杂志》：在本次更新中，我们手工检索了这些期刊最近三年的文章（截至2019年11月）。
选择标准
我们检索了所有关于组织学诊断为原发性脑肿瘤患者抑郁症任何药物治疗的随机对照试验、对照临床试验、队列研究和病例对照研究。
数据收集与分析
没有研究符合纳入标准。
主要结果
我们未发现评估原发性脑肿瘤患者抑郁症任何药物治疗益处的合格研究。
作者结论
我们未发现高质量研究调查原发性脑肿瘤患者抑郁症药物治疗的价值。需要进行随机对照试验和详细的前瞻性研究，以指导有效治疗这种常见且重要的脑肿瘤并发症。自本系统评价的上一版本以来，没有相关新文献提供额外信息来改变这些结论。
Zotero 插件